Mereo BioPharma

BOOST Pharma

This company develops an off-the-shelf therapy to treat children born with severe osteogenesis imperfecta, also known as brittle bone disease.

Ultragenyx

This biopharmaceutical company develops and commercialises therapies for patients with serious rare and ultra-rare genetic diseases.

Mirum

Mirum Pharmaceuticals develops and commercialises therapies for patients with rare cholestatic liver diseases and other debilitating conditions.

GondolaBio

This biopharmaceutical company develops clinical-stage and preclinical medicinal therapeutics for patients living with rare genetic diseases.

VectivBio

This company develops biopharmaceutical treatments for severe rare gastrointestinal conditions, including short bowel syndrome, for patients with orphan diseases.

Angitia Biopharmaceuticals

The company develops biologic therapies for patients with serious musculoskeletal diseases, including osteoporosis and osteogenesis imperfecta.

Castle Creek Biosciences

This company develops cell and gene therapies for patients suffering from rare genetic skin and connective tissue diseases.

Northsea Therapeutics

This company develops structurally engineered fatty acid drugs for patients with metabolic, inflammatory, and fibrotic diseases such as rare liver disorders.